Lenalidomide Capsules
Multiple Myeloma, Myelodysplastic Syndromes
10mg
Lenalidomide 10mg hard capsules, used in the management of multiple myeloma and myelodysplastic syndromes. A thalidomide analogue and immunomodulator.
From$6.51/ capsuleView
Lenalidomide
Lenalidomide (Revlimid) is an immunomodulatory medication used to support the management of specific blood-based conditions. It provides a therapeutic option by regulating cellular immune responses to abnormal cells. One formulated product is listed.
Key points
- Used specifically for the blood cancers multiple myeloma and myelodysplastic syndromes, integrated into wider treatment regimens for these conditions.
- Reduces the release of proteins that feed tumour-related blood vessel growth while priming the immune system against abnormal cells.
- Baseline monitoring of blood counts, heart and kidney health is required given how the treatment affects these systems.
What is Lenalidomide?
Lenalidomide is an oral agent that modulates the immune system to inhibit the development of abnormal cells. It serves as a targeted therapy, often integrated into broad treatment regimens to address complex hematological profiles. By altering the signaling pathways that support disease progression, it assists in managing symptom severity and cellular health.
What Lenalidomide is used for
The medication is primarily intended for the management of Multiple Myeloma and Myelodysplastic Syndromes. These clinical applications require structured monitoring to ensure the therapy is appropriate for the individual’s specific blood counts and health state.
How does Lenalidomide work?
Lenalidomide functions by interfering with the development and survival of abnormal cells in the bone marrow and blood. It acts as an immunomodulator, meaning it helps to prime the immune system to recognize and attack cells that are not functioning correctly, while reducing the release of proteins that otherwise promote tumour-related vascular growth.
Lenalidomide brands and forms
The originator brand is Revlimid, with widely utilised generic formulations available within Oncology Support profiles. The primary form is: Capsule, hard. These formulations are designed to meet consistent standards for oral administration.
Safety overview for Lenalidomide
What to check before using this medicine
Patients require baseline blood count monitoring and an assessment of cardiovascular and kidney health. Specific attention is given to pre-existing conditions that may influence the body’s ability to tolerate the medication.
Possible reactions and tolerability
Common considerations involve fatigue, changes in blood cell counts, and localized sensitivities. It is common for clinical teams to observe patient response to identify and manage these effects early.
Interactions and health factors
It is essential to review all concurrent medications, including supplements, to prevent unwanted interactions. Product labelling and verified clinical sources remain the correct references for specific contraindications, interactions and reactions.